Skip to content
Screener

Corcept Therapeutics CORT Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$202.1MMiss by $52.8M
EPS$0.20Miss by $0.13
Revenue estimate$254.9M
EPS estimate$0.33

Next report

Nov 4, 2026 (in a month)
Revenue estimate$323.9M
EPS estimate$0.81

Financials

Q4 2025

Income statement

See full
Revenue$202.1M+11.1%
Gross profit$199.6M+11.5%
Operating income$4.5M-82.2%
Net income$24.3M-21.0%
EPS (diluted)$0.20-20.0%

Balance sheet

See full
Cash & equivalents$121.7M-5.4%
Total debt$6.1M-12.0%
Total equity$647.8M-4.7%
Total assets$836.7M-0.5%

Cash flow

See full
Operating cash flow$38.4M-35.2%
CapEx$50.0K-58.7%
Free cash flow$38.4M-35.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.66B-30.7%
Enterprise value$3.54B-31.3%
P/E36.7×-0.7×
P/S4.8×-3.0×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin5.9%-14.4pp
Net margin13.1%-7.8pp
FCF margin18.6%-10.4pp

Returns & leverage

See full
Return on equity15%-8.8pp
Debt / equity0×0.0×
Current ratio2.9×-0.4×

FAQ

When did Corcept Therapeutics report Q4 2025 earnings?
Corcept Therapeutics (CORT) reported Q4 2025 earnings on February 24, 2026 after market close.
What were Corcept Therapeutics's Q4 2025 revenue and EPS?
Corcept Therapeutics reported revenue of $202.1M and eps of $0.20 for Q4 2025.
Did Corcept Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $254.9M by $52.8M. EPS missed the consensus estimate of $0.33 by $0.13.
How did Corcept Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.1% from $181.9M a year earlier and eps declined 23.1% from $0.26.
Where can I find Corcept Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-011080) and the 10-K periodic report (0001628280-26-011091) directly on SEC EDGAR. The filing index links above go to sec.gov.